A one-time treatment tweaked their genes — and lowered their cholesterol

Key Points:

• Christos Soteriou, diagnosed with familial hypercholesterolemia, underwent a groundbreaking CRISPR gene-editing trial that significantly lowered his cholesterol levels after traditional treatments failed.
• The trial targeted the ANGPTL3 gene in the liver to reduce blood lipid levels, showing promising results with up to a 49% reduction in LDL cholesterol and a 55% reduction in triglycerides among participants.
• This one-time gene-editing therapy represents a potential paradigm shift in heart disease management, offering a durable alternative to lifelong cholesterol-lowering medications that many patients struggle to maintain.
• While early results are encouraging, long-term safety concerns remain, including possible off-target effects of CRISPR, prompting ongoing monitoring and development of potentially safer methods like base editing.
• Researchers and cardiologists are optimistic that such gene-editing treatments could become widely available by the early 2030s, potentially providing lifelong cardiovascular protection, especially for high-risk patients.